Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS M SILER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1881633931
CMS profile
84851
Location
SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$80,784.86

218 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 218 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS M SILER

NPI 1881633931 · CMS profile ID 84851

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SAINT CHARLES, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 218 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881633931?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS M SILER, NPI 1881633931, CMS profile ID 84851. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 218 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881633931?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). THOMAS M SILER, NPI 1881633931, CMS profile ID 84851. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 218 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881633931?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
THOMAS M SILER, NPI 1881633931, CMS profile ID 84851, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 218 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881633931?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

218 matching records · $80,784.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 218 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 218.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $340.8607/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671406015 CMS
GlaxoSmithKline, LLC. $65.0007/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671516347 CMS
GlaxoSmithKline, LLC. $8.4107/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670892445 CMS
JAZZ PHARMACEUTICALS INC. $17.6507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684166877 CMS
Genentech USA, Inc. $20.7107/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681381447 CMS
Mylan Specialty L.P. $17.1907/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694790459 CMS
Mylan Specialty L.P. $142.9007/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694759065 CMS
Mylan Specialty L.P. $786.1307/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694759845 CMS
Mylan Specialty L.P. $1,608.0007/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694811631 CMS
AstraZeneca Pharmaceuticals LP $975.0007/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685512469 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.0607/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700467849 CMS
Electromed, Inc. $16.4907/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705242227 CMS
Pulmonx Corporation $63.1907/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690765233 CMS
GlaxoSmithKline, LLC. $13.8506/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670316225 CMS
GlaxoSmithKline, LLC. $38.1706/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670323287 CMS
GlaxoSmithKline, LLC. $22.8006/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670600717 CMS
GlaxoSmithKline, LLC. $32.0006/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670862033 CMS
GlaxoSmithKline, LLC. $35.0406/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670994113 CMS
GlaxoSmithKline, LLC. $191.8206/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670778047 CMS
GlaxoSmithKline, LLC. $93.0006/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671060541 CMS
GlaxoSmithKline, LLC. $120.1006/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671411049 CMS
Mylan Specialty L.P. $1,132.5006/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760513 CMS
Mylan Specialty L.P. $318.7506/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760523 CMS
Mylan Specialty L.P. $577.5006/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760525 CMS
GlaxoSmithKline, LLC. $11.5006/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670808915 CMS
AstraZeneca Pharmaceuticals LP $12.0806/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685819925 CMS
JAZZ PHARMACEUTICALS INC. $17.5706/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684166875 CMS
Mylan Specialty L.P. $12.7206/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694787401 CMS
Mylan Specialty L.P. $13.1906/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694759063 CMS
Circassia Pharmaceuticals Inc $13.6906/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660220723 CMS
GENZYME CORPORATION $22.7506/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694042317 CMS
GlaxoSmithKline, LLC. $13.4806/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671054843 CMS
Genentech USA, Inc. $11.1905/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681259981 CMS
AstraZeneca Pharmaceuticals LP $12.4705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685744859 CMS
GlaxoSmithKline, LLC. $623.5405/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670972233 CMS
GlaxoSmithKline, LLC. $15.9305/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671156617 CMS
Grifols USA, LLC $13.0905/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692589007 CMS
GlaxoSmithKline, LLC. $3,600.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671455401 CMS
GENZYME CORPORATION $30.9805/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694112759 CMS
AstraZeneca Pharmaceuticals LP $23.2405/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685766313 CMS
AstraZeneca Pharmaceuticals LP $127.5205/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685620647 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.7805/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700467851 CMS
GlaxoSmithKline, LLC. $33.0005/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671001131 CMS
Mylan Specialty L.P. $14.0005/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760629 CMS
Mylan Specialty L.P. $3,216.0005/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760729 CMS
Mylan Specialty L.P. $977.9905/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760731 CMS
Mylan Specialty L.P. $61.5605/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694760733 CMS
Mylan Specialty L.P. $268.8805/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694811159 CMS
GlaxoSmithKline, LLC. $10.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671306329 CMS
Circassia Pharmaceuticals Inc $12.0805/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660220721 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,784.86 218
PY2020 $22,999.05 114
PY2021 $13,871.21 74
PY2022 $4,208.01 55
PY2023 $17,397.05 70
PY2024 $3,975.24 80
PY2025 $3,265.23 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,127,176.46 53
PY2024 Principal investigator $1,091,525.15 85
PY2023 Principal investigator $861,893.62 122
PY2022 Recipient $1,467.69 8
PY2022 Principal investigator $674,631.44 82
PY2021 Principal investigator $568,997.60 56
PY2020 Principal investigator $306,899.63 31
PY2019 Recipient $1,469.36 18
PY2019 Principal investigator $697,312.93 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Verona Pharma, Inc. $239,069.87 12/17/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891531
Principal investigator 1 Genentech, Inc. $1,752.00 12/11/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625514
Principal investigator 1 Genentech, Inc. $512.00 12/09/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625509
Principal investigator 1 Verona Pharma, Inc. $5,619.52 12/05/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891735
Principal investigator 1 SANOFI US SERVICES INC. $4,194.34 12/02/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129457
Principal investigator 1 Genentech, Inc. $1,482.00 11/12/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625503
Principal investigator 1 Verona Pharma, Inc. $318,501.04 11/12/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891733
Principal investigator 1 Verona Pharma, Inc. $11,764.56 11/05/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891731
Principal investigator 1 Genentech, Inc. $2,723.00 11/03/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625506
Principal investigator 1 Genentech, Inc. $876.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625500
Principal investigator 1 Verona Pharma, Inc. $8,700.00 09/26/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891629
Principal investigator 1 Verona Pharma, Inc. $1,500.00 09/26/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891631
Principal investigator 1 SANOFI US SERVICES INC. $2,619.77 09/03/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129454
Principal investigator 1 Genentech, Inc. $4,475.00 08/26/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625497
Principal investigator 1 SANOFI US SERVICES INC. $494.00 08/11/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129450
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,361.41 08/07/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185545717
Principal investigator 1 GlaxoSmithKline, LLC. $1,032.00 07/25/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192138217
Principal investigator 1 Genentech, Inc. $13,140.00 06/17/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625482
Principal investigator 1 Chiesi USA, Inc. $1,875.00 06/16/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403189
Principal investigator 1 Chiesi USA, Inc. $3,555.98 06/16/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403193
Principal investigator 1 Chiesi USA, Inc. $285.18 06/16/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403197
Principal investigator 1 Genentech, Inc. $19,082.00 05/20/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625489
Principal investigator 1 SANOFI US SERVICES INC. $10,959.00 05/19/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129442
Principal investigator 1 Genentech, Inc. $1,248.00 05/15/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625492
Principal investigator 1 Genentech, Inc. $1,650.00 05/07/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625472
Principal investigator 1 Verona Pharma, Inc. $9,288.92 05/07/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892719
Principal investigator 1 Verona Pharma, Inc. $1,500.00 05/07/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892721
Principal investigator 1 GlaxoSmithKline, LLC. $2,799.00 05/02/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140755
Principal investigator 1 GlaxoSmithKline, LLC. $1,562.00 05/02/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192140763
Principal investigator 1 Genentech, Inc. $16,739.00 04/24/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625475
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,833.42 04/09/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185545709
Principal investigator 1 Genentech, Inc. $8,663.00 04/08/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625485
Principal investigator 1 SANOFI US SERVICES INC. $4,258.16 04/07/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129427
Principal investigator 1 Genentech, Inc. $292.00 04/01/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625478
Principal investigator 1 SANOFI US SERVICES INC. $5,165.54 03/17/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129418
Principal investigator 1 Verona Pharma, Inc. $4,209.00 03/14/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
Effect of Ensifentrine Treatment on CAT Score No dispute reported 06/30/2026 1232892633
Principal investigator 1 Verona Pharma, Inc. $200.00 03/06/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
Effect of Ensifentrine Treatment on CAT Score No dispute reported 06/30/2026 1232892635
Principal investigator 1 AstraZeneca UK Limited $26,889.91 03/05/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185545713
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,496.01 02/26/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185545715
Principal investigator 1 Verona Pharma, Inc. $17,151.62 02/19/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892689
Principal investigator 1 Genentech, Inc. $22,644.00 02/18/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625469
Principal investigator 1 SANOFI US SERVICES INC. $10,177.46 02/18/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129414
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,498.47 02/14/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1185545707
Principal investigator 1 Genentech, Inc. $2,394.00 02/13/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625452
Principal investigator 1 Genentech, Inc. $252.00 02/13/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625460
Principal investigator 1 Genentech, Inc. $23,102.00 02/06/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625457
Principal investigator 1 Amgen Inc. $47,351.47 01/27/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246644699
Principal investigator 1 Verona Pharma, Inc. $16,201.20 01/27/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
Effect of Ensifentrine Treatment on CAT Score No dispute reported 06/30/2026 1232892637
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,719.82 01/22/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS, PC
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185545711
Principal investigator 1 SANOFI US SERVICES INC. $5,567.08 01/21/2025 Non-covered Recipient Entity
Midwest Chest Consultants, Pc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226129406
Principal investigator 1 Verona Pharma, Inc. $40,736.89 01/08/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892685
Principal investigator 1 Verona Pharma, Inc. $73,015.82 01/08/2025 Non-covered Recipient Entity
Midwest Chest Consultants PC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892687
Principal investigator 1 Genentech, Inc. $27,997.00 01/07/2025 Non-covered Recipient Entity
MIDWEST CHEST CONSULTANTS PC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625465